Celldex TherapeuticsCLDX
Market Cap: $2.9B
About: Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
Employees: 160
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
65% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 49
20% more funds holding in top 10
Funds holding in top 10: 5 [Q1] → 6 (+1) [Q2]
2.58% less ownership
Funds ownership: 108.17% [Q1] → 105.59% (-2.58%) [Q2]
9% less funds holding
Funds holding: 196 [Q1] → 179 (-17) [Q2]
12% less capital invested
Capital invested by funds: $2.92B [Q1] → $2.58B (-$349M) [Q2]
44% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 39
80% less call options, than puts
Call options by funds: $3.39M | Put options by funds: $17M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Wells Fargo Derek Archila 53% 1-year accuracy 16 / 30 met price target | 15%downside $37 | Equal-Weight Maintained | 12 Aug 2024 |
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target | 83%upside $80 | Buy Reiterated | 12 Aug 2024 |
Cantor Fitzgerald Kristen Kluska 59% 1-year accuracy 48 / 81 met price target | 53%upside $67 | Overweight Reiterated | 30 Jul 2024 |
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target | 83%upside $80 | Buy Reiterated | 30 Jul 2024 |
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target | 83%upside $80 | Buy Reiterated | 16 Jul 2024 |